Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
Comparison the Seroconversion Rate Between Two-dose and Three-dose Regimens of Heplisav B Among Patients With Cirrhosis, a Randomized-control Prospective Study.
Mercy Medical Center
200 participants
Sep 14, 2020
INTERVENTIONAL
Conditions
Summary
Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.
Eligibility
Inclusion Criteria1
- \- All the cirrhosis patients more than 18 years old presented to the hepatology clinic in Mercy Medical Center between 09/2020 and 07/2021 who do not have immunity against Hepatitis B (defined as anti-HBs titer < 10 mIU/ml) will be recruited.
Exclusion Criteria4
- Anyone who has had a serious allergic reaction to a prior dose of the hepatitis B vaccine, a component of the hepatitis B vaccine, or yeast should not receive the hepatitis B vaccine.
- Those who had previous exposure to hepatitis B.
- Post liver transplant patients.
- Less than 18 years old.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Investigators will randomly assign patients into a 2-dose regimen.
Investigators will randomly assign patients into a 3-dose regimen.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04588077